Air enters the device
Inhaled or exhaled airflow is routed through a defined device pathway rather than relying only on passive mask material.
How it works
Plain-English mechanism of action.
MaskZero is designed to act at the point of breath: air enters a device pathway, target pathogens are captured or exposed, contained UV-C irradiance acts inside the chamber, and cleaned airflow supports wearer protection and source control.
FDA status: Regulatory status available under NDA or partner request.
Pathogens are captured or exposed
The airflow path is designed to bring viable viral particles into contact with capture or exposure zones.
Contained UV-C neutralizes viable virus
UV-C energy is intended to act within a contained chamber. Performance depends on wavelength, irradiance, dose, dwell time, and validated geometry.
Cleaned airflow supports protection
The design goal is cleaned airflow that may support wearer protection and source control, subject to final testing, labeling, and regulatory review.
UV-C wavelength and exposure.
UV-C germicidal performance is generally governed by wavelength, irradiance, distance, exposure time, airflow dwell time, chamber geometry, target organism, and shielding. MaskZero public copy does not publish validated dose claims; qualified reviewers can request the technical brief and testing package.
Safety containment.
The safety architecture is intended to keep UV-C energy inside the device path, away from user skin and eyes. Final safety statements must be supported by device testing, instructions for use, risk management documentation, and regulatory review.
What the device claims.
- Patented active respiratory protection device concept.
- Designed to capture or expose pathogens within the airflow path.
- Designed to use contained UV-C technology for viral neutralization.
- Intended for pandemic preparedness conversations with qualified buyers and partners.
What the device does not claim on this public site.
- No public claim of FDA clearance is made here.
- No public replacement claim for N95, elastomeric respirators, or PAPRs is made.
- No quantified viral kill rate is published without evidence review.
- No diagnosis, treatment, cure, or prevention claim is made beyond the qualified device concept language above.
Comparison
N95, elastomeric respirators, PAPRs, and MaskZero.
This comparison supports diligence framing, not final labeling.
| Category | N95 | Elastomeric Respirator | PAPR | MaskZero |
|---|---|---|---|---|
| Primary mechanism | Passive filtration | Reusable filtration cartridges | Powered filtered airflow | Device-specific airflow path with capture/exposure and contained UV-C concept |
| Pathogen neutralization | No active kill claim | No active kill claim | No active kill claim | Claimed / evidence-linked, subject to validation |
| Reuse model | Limited | Yes | Yes | Likely, subject to final design and instructions for use |
| Procurement fit | Healthcare standard | Healthcare / industrial | Healthcare / industrial | Pandemic readiness, pilot, stockpile, and partner review pathway |